Just as a rising tide is said to lift all boats, so too is a new FDA clearance expanding the reach of all of Boston Scientific’s WaveWriter spinal cord stimulation systems. The devices—which include ...
MARLBOROUGH, Mass., Jan. 14, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The ...
Adrian-based Michigan Pain Specialists providers are using the Spectra WaveWriter Spinal Cord Stimulator System to help patients cope with chronic pain, Lenconnect.com reports. Here's what you should ...
Boston Scientific, Inc. BSX recently received FDA approval for an expanded indication of the WaveWriter Alpha Spinal Cord Stimulator (“SCS”) Systems. With this approval, the system will be available ...
LONDON, UK / ACCESSWIRE / January 16, 2018 / Active-Investors.com has just released a free research report on Boston Scientific Corp. (NYSE: BSX). If you want access to this report all you need to do ...
Boston Scientific just won FDA approval for the first spinal cord neurostimulator system to provide both paresthesia-based and sub-perception therapy at the same time. The WaveWriter system delivers ...
Boston Scientific Corp. notched another win with the U.S. FDA approval of its spinal cord stimulator (SCS), Wavewriter, for treatment of non-surgical back pain just a week after receiving the agency’s ...
MARLBOROUGH, Mass., Sept. 30, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results